Inventor · disambiguated record
Masafumi Matsuo
Also filed as: MATSUO MASAFUMI
15 granted patents·5 pending applications·656 citations·filing 2000–2022
94Inventor score
Files withKNC LABORATORIES CO LTD5DAIICHI SANKYO CO LTD4JAPAN CHEM RES3MATSUO MASAFUMI3HAGIWARA MASATOSHI1
Top patents by PatentIndex Score
20 records- 0197US9657050B2ENA nucleic acid pharmaceuticals capable of modifying splicing of mRNA precursorsDAIICHI SANKYO CO LTD·Filed 2015·Granted May 23, 2017·31 cites·18 claims
- 0297US6653466B2Pharmaceutical composition for treatment of duchenne muscular dystrophyJAPAN CHEM RES·Filed 2001·Granted Nov 25, 2003·132 cites·16 claims
- 0395US9657049B2ENA nucleic acid pharmaceuticals capable of modifying splicing of mRNA precursorsMATSUO MASAFUMI·Filed 2012·Granted May 23, 2017·31 cites·18 claims
- 0495US8624019B2ENA nucleic acid drugs modifying splicing in mRNA precursorMATSUO MASAFUMI·Filed 2010·Granted Jan 7, 2014·38 cites·1 claims
- 0595US6727355B2Pharmaceutical composition for treatment of Duchenne muscular dystrophyJAPAN CHEM RES·Filed 2001·Granted Apr 27, 2004·152 cites·2 claims
- 0694US7902160B2ENA nucleic acid drugs modifying splicing in mRNA precursorNONPROFIT ORGANIZATION TRANSLATIONAL RES ORGANIZATION OF DUCHENNE MUSCULAR DYSTROPHY·Filed 2003·Granted Mar 8, 2011·96 cites·52 claims
- 0794US6653467B1Medicament for treatment of Duchenne muscular dystrophyJCR PHARMACEUTICAL CO LTD·Filed 2000·Granted Nov 25, 2003·166 cites·2 claims
- 0885US9243026B2ENA nucleic acid pharmaceuticals capable of modifying splicing of mRNA precursorsDAIICHI SANKYO CO LTD·Filed 2014·Granted Jan 26, 2016·5 cites·15 claims
- 0974US11958878B2Therapeutic agent for glycogen storage disease type IADAIICHI SANKYO CO LTD·Filed 2019·Granted Apr 16, 2024·1 cites·6 claims
- 1060US8719650B2Self-diagnosis system and test circuit determination methodMATSUO MASAFUMI·Filed 2011·Granted May 6, 2014·1 cites·16 claims
- 1159US6548284B1Membrane-bound metalloprotease and soluble secreted form thereofJAPAN CHEM RES·Filed 2000·Granted Apr 15, 2003·3 cites·9 claims
- 1253US9358246B2Readthrough inducing agent and drug for treating genetic disease caused by nonsense mutationMICROBIAL CHEM RES FOUND·Filed 2014·Granted Jun 7, 2016·0 cites·6 claims
- 1351US2024229036A9Nucleic acid medicine expressing splicing variant of myostatinKNC LABORATORIES CO LTD·Filed 2022·Application pending·0 cites
- 1450US2021207136A1Myocardial dysfunction therapeutic agentDAIICHI SANKYO CO LTD·Filed 2019·Application pending·0 cites
- 1549US12202869B2Inhibition of myostatin signal by myostatin splice variant-derived protein and utilization thereofKNC LABORATORIES CO LTD·Filed 2020·Granted Jan 21, 2025·0 cites·6 claims
- 1649US2023272403A1Antisense oligonucleotide inducing exon skipping of angiotensin converting enzyme 2 geneKNC LABORATORIES CO LTD·Filed 2021·Application pending·0 cites
- 1741US2022220478A1Nucleic acid drug suppressing production of myostatin gene mrnaKNC LABORATORIES CO LTD·Filed 2020·Application pending·0 cites
- 1840US2013005953A1Readthrough Inducing Agent and Drug for Treating Genetic Disease Caused by Nonsense MutationMATSUDA RYOICHI·Filed 2012·Application pending·0 cites
- 1938US10174319B2Nucleic acid drug for inducing skipping of variant exon of CD44 gene and increasing expression of normal type CD44 mRNAKNC LABORATORIES CO LTD·Filed 2015·Granted Jan 8, 2019·0 cites·13 claims
- 2035US9241929B2Prophylactic or ameliorating agent for genetic diseasesHAGIWARA MASATOSHI·Filed 2011·Granted Jan 26, 2016·0 cites·10 claims
Join the waitlist — get patent alerts
Get an alert when Masafumi Matsuo files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →